×
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.89 (+2.08%)
MSFT   267.83 (+0.61%)
META   172.11 (+1.38%)
GOOGL   2,359.77 (+2.98%)
AMZN   116.35 (+1.77%)
TSLA   733.66 (+5.53%)
NVDA   157.87 (+4.34%)
NIO   22.55 (+8.26%)
BABA   123.44 (+3.63%)
AMD   78.98 (+4.82%)
MU   58.25 (+1.53%)
CGC   2.72 (+2.64%)
T   21.13 (+0.19%)
GE   62.46 (+1.45%)
F   11.59 (+4.79%)
DIS   96.98 (+0.94%)
AMC   14.19 (+12.89%)
PFE   53.16 (+0.78%)
PYPL   74.67 (+1.95%)
NFLX   189.00 (+2.68%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.89 (+2.08%)
MSFT   267.83 (+0.61%)
META   172.11 (+1.38%)
GOOGL   2,359.77 (+2.98%)
AMZN   116.35 (+1.77%)
TSLA   733.66 (+5.53%)
NVDA   157.87 (+4.34%)
NIO   22.55 (+8.26%)
BABA   123.44 (+3.63%)
AMD   78.98 (+4.82%)
MU   58.25 (+1.53%)
CGC   2.72 (+2.64%)
T   21.13 (+0.19%)
GE   62.46 (+1.45%)
F   11.59 (+4.79%)
DIS   96.98 (+0.94%)
AMC   14.19 (+12.89%)
PFE   53.16 (+0.78%)
PYPL   74.67 (+1.95%)
NFLX   189.00 (+2.68%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.89 (+2.08%)
MSFT   267.83 (+0.61%)
META   172.11 (+1.38%)
GOOGL   2,359.77 (+2.98%)
AMZN   116.35 (+1.77%)
TSLA   733.66 (+5.53%)
NVDA   157.87 (+4.34%)
NIO   22.55 (+8.26%)
BABA   123.44 (+3.63%)
AMD   78.98 (+4.82%)
MU   58.25 (+1.53%)
CGC   2.72 (+2.64%)
T   21.13 (+0.19%)
GE   62.46 (+1.45%)
F   11.59 (+4.79%)
DIS   96.98 (+0.94%)
AMC   14.19 (+12.89%)
PFE   53.16 (+0.78%)
PYPL   74.67 (+1.95%)
NFLX   189.00 (+2.68%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.89 (+2.08%)
MSFT   267.83 (+0.61%)
META   172.11 (+1.38%)
GOOGL   2,359.77 (+2.98%)
AMZN   116.35 (+1.77%)
TSLA   733.66 (+5.53%)
NVDA   157.87 (+4.34%)
NIO   22.55 (+8.26%)
BABA   123.44 (+3.63%)
AMD   78.98 (+4.82%)
MU   58.25 (+1.53%)
CGC   2.72 (+2.64%)
T   21.13 (+0.19%)
GE   62.46 (+1.45%)
F   11.59 (+4.79%)
DIS   96.98 (+0.94%)
AMC   14.19 (+12.89%)
PFE   53.16 (+0.78%)
PYPL   74.67 (+1.95%)
NFLX   189.00 (+2.68%)
NASDAQ:OPK

OPKO Health Stock Forecast, Price & News

$2.82
+0.08 (+2.92%)
(As of 07/7/2022 01:04 PM ET)
Add
Compare
Today's Range
$2.72
$2.84
50-Day Range
$2.33
$3.20
52-Week Range
$2.17
$5.25
Volume
51,215 shs
Average Volume
5.82 million shs
Market Capitalization
$1.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

OPKO Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
96.4% Upside
$5.50 Price Target
Short Interest
Bearish
13.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$4.67 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.14) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.10 out of 5 stars

Medical Sector

338th out of 1,433 stocks

Pharmaceutical Preparations Industry

156th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPKO Health logo

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Stock News Headlines

OPKO Health (NASDAQ:OPK) Sets New 12-Month Low at $2.19
OPK July 22nd Options Begin Trading
Why Opko Health Stock Is Jumping Today
OPKO Health Misses Q1 EPS by 2c
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
5,767
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/07/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+95.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
2 Analysts

Profitability

Net Income
$-30,140,000.00
Pretax Margin
-7.85%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Cash Flow
$0.08 per share
Book Value
$2.47 per share

Miscellaneous

Free Float
402,304,000
Market Cap
$1.92 billion
Optionable
Optionable
Beta
1.87














OPKO Health Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPKO Health stock.
View analyst ratings for OPKO Health
or view top-rated stocks.

What is OPKO Health's stock price forecast for 2022?

2 analysts have issued 1-year price targets for OPKO Health's stock. Their OPK stock forecasts range from $5.00 to $6.00. On average, they expect OPKO Health's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 95.0% from the stock's current price.
View analysts' price targets for OPKO Health
or view top-rated stocks among Wall Street analysts.

How has OPKO Health's stock price performed in 2022?

OPKO Health's stock was trading at $4.81 at the start of the year. Since then, OPK stock has decreased by 41.4% and is now trading at $2.82.
View the best growth stocks for 2022 here
.

When is OPKO Health's next earnings date?

OPKO Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for OPKO Health
.

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) posted its quarterly earnings data on Monday, May, 9th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The biotechnology company earned $329.20 million during the quarter, compared to analyst estimates of $331.45 million. OPKO Health had a negative trailing twelve-month return on equity of 6.86% and a negative net margin of 7.49%. The firm's revenue was down 39.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.05 earnings per share.
View OPKO Health's earnings history
.

Who are OPKO Health's key executives?

OPKO Health's management team includes the following people:
  • Dr. Phillip Frost Ph.D., Chairman & CEO (Age 86, Pay $971.6k)
  • Dr. Jane H. Hsiao M.B.A., MBA, Ph.D., Vice Chairman & Chief Technical Officer (Age 75, Pay $911.6k)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 44, Pay $911.6k)
  • Mr. Steven D. Rubin Esq., J.D., Exec. VP of Admin. & Director (Age 62, Pay $821.6k)
  • Dr. Jon R. Cohen M.D., Sr. VP & Director (Age 67, Pay $1.74M)
  • Dr. Elias A. Zerhouni M.D., Pres & Vice Chairman (Age 71)
  • Dr. Arie Gutman, Pres of API (Age 68)
  • Mr. James DeMarco, Sr. VP of Pharmaceutical Sales
  • Dr. Akhtar Ashfaq, Sr. VP of Clinical R&D and Medical Affairs
  • Ms. Jane Pine Wood Esq., J.D., Chief Legal Officer of Bio-Reference Laboratories (Age 59)

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health CEO Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among OPKO Health's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

How do I buy shares of OPKO Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $2.82.

How much money does OPKO Health make?

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.92 billion and generates $1.77 billion in revenue each year. The biotechnology company earns $-30,140,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does OPKO Health have?

OPKO Health employs 5,767 workers across the globe.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for OPKO Health is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.